Quick Answer
Sarepta Therapeutics, Inc. reported Long Term Debt of $1.48 million for the year ending 2014.
- Sarepta Therapeutics, Inc. showed a decrease of -6.3% in Long Term Debt from 2013 to 2014.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2015.
- XBRL data for this metric is available from 2010 to 2014 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $1.80 million | Q3 2011: $1.78 million | Q1 2012: $1.74 million | Q2 2012: $1.71 million | Q3 2012: $1.69 million | Q1 2013: $1.65 million | Q2 2013: $1.62 million | Q3 2013: $1.60 million | Q1 2014: $1.55 million | Q2 2014: $1.53 million | Q3 2014: $1.50 million | Q4 2014: $1.48 million | Q1 2015: $1.45 million.
- Over the full 5 years of available data (2010 to 2014), Sarepta Therapeutics, Inc.'s Long Term Debt has declined by 19.9%.
- Historical annual values: Fiscal year 2014: $1.48 million | Fiscal year 2013: $1.58 million | Fiscal year 2012: $1.67 million | Fiscal year 2011: $1.76 million | Fiscal year 2010: $1.84 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: